Home / Pharma News

Pharma News

Teva and Takeda partner for generics in Japan

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical (Takeda) announced on 30 November 2015 that they had made a partnership to provide generics in Japan.

Generic injectable prices stay high even after shortages resolved

Hospitals that have been struggling with shortages and subsequent high prices are now complaining that even after supply gets back to normal prices remain high. 

Mylan will not be acquiring Perrigo

Generics company Mylan has failed in its lengthy multi-billion dollar hostile bid to acquire competing generics company Perrigo.

Pfizer cuts some biosimilars after Hospira deal

After completing its US$17 billion acquisition of Hospira, Pfizer is cutting some of its biosimilar collaborations with South Korean drugmaker Celltrion.

Merck Millipore to collaborate with Turkish firm on biosimilars

The Life Science division of Merck, Merck Millipore and Turkish biosimilars start-up Turgut Ilaç are to collaborate on biosimilars.

Teva acquires Mexican drugmaker Rimsa

Israeli generics giant Teva Pharmaceutical Industries (Teva) is expanding its presence in emerging markets with its acquisition of Mexico-based Representaciones e Investigaciones Medicas SA de CV (Rimsa), a specialty drugmaker with a portfolio of products and patents across Latin America.

Mylan goes after Perrigo

US generics manufacturer Mylan announced on 14 September 2015 that it had officially commenced its formal offer to acquire all outstanding ordinary shares of rival Ireland-based generics maker Perrigo Company (Perrigo).

Epirus expands biosimilars pipeline with Bioceros acquisition

US-based Epirus Biopharmaceuticals (Epirus) announced on 9 September 2015 that it has acquired Netherlands-based biopharmaceutical company Bioceros Holding (Bioceros).

UCB sells generics unit to Lannett

Belgium-based biopharmaceutical company UCB announced on 2 September 2015 that it would sell its US specialty generics business, Kremers Urban, to US generics company Lannett for US$1.23 billion in cash plus contingent payments.

US FTC clears Pfizer’s purchase of Hospira

Pharma giant Pfizer announced on 24 August 2015 that the US Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of US-based injectable generics specialist and biosimilars maker Hospira.